Injectable and inhalable formulations
US12318477B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Nov 18, 2022 |
| Grant date | Jun 3, 2025 |
| Priority date | — |
| Expiry date | Nov 18, 2042 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K47/12
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to aqueous pharmaceutical formulations, methods for their production, and uses thereof. The aqueous pharmaceutical formulations comprise a salt of an optionally substituted dimethyltryptamine compound and water, with a pH from 5 to 6.5, preferably from about 5 to about 6, and a concentration of the optionally substituted dimethyltryptamine compound of about 10 mg/ml or greater as the freebase equivalent. These formulations can comprise an effective dose of an optionally substituted dimethyltryptamine compound for use in psychedelic assisted therapy within a volume of 5 ml or less. Such formulations are surprisingly suitable both for intramuscular injection and nebulised inhalation, being both stable and clinically acceptable, and have potential uses in the treatment of psychiatric or neurological disorders.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.